


L1

STR



O @14

O~ Ak  
@15 16

O~ Cb  
@17 18

O~ Ak~ Cb  
@19 20 21

Search for  $R = (dz)$  (claim 22)

Ak @22

VAR G2=H/22

NODE ATTRIBUTES:

CONNECT	IS	E2	RC	AT	1
CONNECT	IS	E2	RC	AT	3
CONNECT	IS	E2	RC	AT	6
CONNECT	IS	E3	RC	AT	11
CONNECT	IS	E1	RC	AT	14
CONNECT	IS	E1	RC	AT	16
CONNECT	IS	E1	RC	AT	18
CONNECT	IS	E2	RC	AT	20
CONNECT	IS	E1	RC	AT	21
CONNECT	IS	E1	RC	AT	22

```

DEFAULT MLEVEL IS ATOM
GGCAT   IS SAT  AT 18
GGCAT   IS UNS  AT 21
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X7 C  AT 18
ECOUNT  IS M6 C  AT 21


```

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 22

## STEREO ATTRIBUTES: NONE

L3 2379 SEA FILE=REGISTRY SSS FUL L1  
L5 STR



Ak @22

VAR G1=14/15/17/19

VAR G2=H/22

REP G3=(0-20) A

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 1

CONNECT IS E2 RC AT 3

CONNECT IS E2 RC AT 6

CONNECT IS E3 RC AT 11

CONNECT IS E1 RC AT 14

CONNECT IS E1 RC AT 16

CONNECT IS E1 RC AT 18

CONNECT IS E2 RC AT 20

CONNECT IS E1 RC AT 21

CONNECT IS E1 RC AT 22

DEFAULT MLEVEL IS ATOM

GGCAT IS SAT AT 18

GGCAT IS UNS AT 21

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS X7 C AT 18

ECOUNT IS M6 C AT 21

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE

L6 22 SEA FILE=REGISTRY SUB=L3 SSS FUL L5

L7 9 SEA FILE=HCAPLUS ABB=ON PLU=ON L6

=&gt; d 1b1b abs hitster 17 1-9

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2002:637657 HCAPLUS

DOCUMENT NUMBER: 137:185420

TITLE: Preparation of pyridinedicarboxamide and -dicarboxylic acid derivatives as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses

INVENTOR(S): Barvian, Nicole Chantel; Connor, David Thomas;  
O'brien, Patrick Michael; Ortwine, Daniel Fred; Patt,  
William Chester; Shuler, Kevon Ray; Wilson, Michael  
William  
PATENT ASSIGNEE(S): Warner-Lambert Company, USA  
SOURCE: PCT Int. Appl., 68 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064568	A1	20020822	WO 2002-IB345	20020204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002161000	A1	20021031	US 2002-71073	20020208
PRIORITY APPLN. INFO.: US 2001-268781P P 20010214 OTHER SOURCE(S): MARPAT 137:185420 GI				



AB Selective MMP-13 inhibitors are pyridine derivs. (I; e.g. pyridine-2,4-dicarboxylic acid bis(3-methoxybenzylamide)) or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 independently are H, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO<sub>2</sub>, NR<sub>4</sub>R<sub>5</sub>, CN, or CF<sub>3</sub>; E is independently O or S; A and B independently are OR<sub>4</sub> or NR<sub>4</sub>R<sub>5</sub>; R<sub>4</sub> and R<sub>5</sub> independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH<sub>2</sub>)<sub>n</sub> aryl, (CH<sub>2</sub>)<sub>n</sub> cycloalkyl, (CH<sub>2</sub>)<sub>n</sub> heteroaryl, or R<sub>4</sub> and R<sub>5</sub> when taken together with the N to which they are attached complete a 3- to 8-membered ring contg. C atoms and optionally contg. a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is 0 to 6. Although I and other Markush structures in the patent show 2,4- derivs., many specific 3,5- derivs. are included in the claims and examples. Combinatorial and non-combinatorial methods were used to prep. numerous claimed compds. and characterization data is reported for about 90 compds. IC<sub>50</sub> values for various claimed compds. show the selectivity towards MMP-13 vs. MMP-1 and MMP-3 and the

potent MMP-13 inhibitory activity (e.g. 0.033  $\mu$ M for pyridine-2,4-dicarboxylic acid bis[[(1,3-benzodioxol-5-yl)methyl]amide]).

IT 449734-48-9P, Pyridine-2,4-dicarboxylic acid bis(3,4-dimethoxybenzylamide)


RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(prepn. of pyridine-2,4-dicarboxamide and -dicarboxylic acid derivs. as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses)

RN 449734-48-9 HCAPLUS

CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3,4-dimethoxyphenyl)methyl]- (9CI)

(CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:555444 HCAPLUS

DOCUMENT NUMBER: 137:124995

TITLE: Preparation of symmetrically disubstituted aromatic compounds and pharmaceutical compositions for the inhibition and/or modulation of human poly(ADP-ribose) glycohydrolase (PARG) activity

INVENTOR(S): Li, Jia-He; Ferraris, Dana V.; Kletzly, Paul W.; Li, Weixing; Wang, Eric Yanjun; Xing, Amy D.; Xu, Weizheng; Zhang, Jie

PATENT ASSIGNEE(S): Guilford Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057211	A1	20020725	WO 2001-US11623	20010410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002132852	A1	20020919	US 2001-829827	20010410





PRIORITY APPLN. INFO.:

US 2001-261738P P 20010116

OTHER SOURCE(S):

MARPAT 137:124995

GI



AB Title compds. I, II, III, etc., pharmaceutically acceptable salts, prodrugs, or metabolites [A = CH<sub>2</sub>, O, S, NH; n = 0-4; Q = (un)substituted aryl, heteroaryl; X = CO, CH<sub>2</sub>, CCl<sub>2</sub>; Y = H, (un)substituted cycloalkyl, aryl, etc.] were prepd. For example, amidation of 9-fluorenone-2,7-diacyl chloride with 3-phenylpropylamine provided fluorenone IV, which inhibited human recombinant PARG at an IC<sub>50</sub> of 1.7 .mu.M. PARG IC<sub>50</sub> inhibition studies for an addnl. 59 examples are provided, ranging in values from 1.1-106 .mu.M. Compds. I-III are useful in treating diseases and disorders due to free radical or reactive oxygen species, induced cellular energy depletion and/or tissue damage resulting from cell damage or death.


IT 443794-52-3P 443794-81-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; prepn. of sym. disubstituted arom. compds. for the inhibition and/or modulation human PARG activity)

RN 443794-52-3 HCAPLUS

CN 3,9-Fluoranthenedicarboxamide, N,N'-bis[(3,4-dimethoxyphenyl)methyl]-(9CI) (CA INDEX NAME)



RN 443794-81-8 HCAPLUS

CN 9H-Fluorene-2,7-dicarboxamide, N,N'-bis[(3,4-dihydroxyphenyl)methyl]-9-oxo-  
(9CI) (CA INDEX NAME)REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:511742 HCAPLUS

DOCUMENT NUMBER: 137:216814

TITLE: N-Acylvanillamides: Development of an Expeditious  
Synthesis and Discovery of New Acyl Templates for  
Powerful Activation of the Vanilloid ReceptorAUTHOR(S): Appendino, Giovanni; Minassi, Alberto; Morello,  
Aniello Schiano; De Petrocellis, Luciano; Di Marzo,  
VincenzoCORPORATE SOURCE: Dipartimento di Scienze Chimiche Alimentari,  
Farmaceutiche e Farmacologiche, Novara, 28100, ItalySOURCE: Journal of Medicinal Chemistry (2002), 45(17),  
3739-3745

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:216814

AB A simple and general synthesis of vanillamides was developed and employed to screen acids from the fatty and isoprenoid pools for new acyl templates of biol. relevance as capsaicin analogs. Potent activation of the human vanilloid receptor 1 (VR1) was obsd. for the vanillamides of certain polyfunctional acids from both pools, showing that the vanilloid activity of capsaicinoids can be substantially improved by introducing polar groups and/or unsaturations on the acyl moiety. The activity of the unsatd. analogs was maintained or even increased by cyclopropanation, while .omega. dimerization led to a substantial increase of activity. Because of the wide structural diversity of the library of compds. screened, these observations could not be translated into a single framework of

structure-activity relationships. Nevertheless, a series of new highly active leads was identified, validating the pharmacol. potential of the unnatural combination of natural building blocks to provide new bioactive compds.

IT 457067-23-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of N-acylvanillamines as templates for vanilloid receptor activators)

RN 457067-23-1 HCAPLUS

CN 10-Eicosenediamide, N,N'-bis[(4-hydroxy-3-methoxyphenyl)methyl]- (9CI)  
(CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

IT 261946-50-3P 457067-21-9P 457067-22-0P


457067-24-2P 457067-25-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of N-acylvanillamines as templates for vanilloid receptor activators)


RN 261946-50-3 HCAPLUS

CN Nonanediamide, N,N'-bis[(4-hydroxy-3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 457067-21-9 HCAPLUS

CN Decanediamide, N,N'-bis[(4-hydroxy-3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 457067-22-0 HCAPLUS


CN Eicosanediamide, N,N'-bis[(4-hydroxy-3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 457067-24-2 HCAPLUS

CN Bicyclo[2.2.1]hept-5-ene-2,3-dicarboxamide, N,N'-bis[(4-hydroxy-3-methoxyphenyl)methyl]-, (1R,2S,3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 457067-25-3 HCAPLUS

CN Bicyclo[2.2.1]hept-5-ene-2,3-dicarboxamide, N,N'-bis[(4-hydroxy-3-methoxyphenyl)methyl]-, (1R,2R,3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:466014 HCAPLUS

DOCUMENT NUMBER: 137:27397

TITLE: Cobalt-porphyrin complexes and use thereof as an anti-obesity agent

INVENTOR(S): Szabo, Tomas R.; Ghosh, Soumitra S.; Davis, Robert E.

PATENT ASSIGNEE(S): Mitokor, USA

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048154	A2	20020620	WO 2001-US48279	20011214
WO 2002048154	A3	20020919		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002041628	A5	20020624	AU 2002-41628	20011214
US 2002165216	A1	20021107	US 2001-20867	20011214
PRIORITY APPLN. INFO.:			US 2000-255960P	P 20001215
			WO 2001-US48279	W 20011214
OTHER SOURCE(S):			MARPAT 137:27397	
GI				



AB Claimed are cobalt-porphyrin (Co-P) complexes I (R1, R2 are various carboxy, oxycarbonyl, carboxamide, aminocarbonyl groups, etc.; R3, R4 = CH:CH2 or Et; L1 and L2 are optional ligands; and with proviso that the cobalt-porphyrin complex has no more than 5% of the redox activity of cobalt mesoporphyrin), or a salt, and their use as antiobesity agents, and related compns. and methods. The Co-P complexes, e.g., prepd. complex I [R1 = R2 = (CH2)2C(O)OMe, R3 = R4 Et, L1 = L2 = H2NCH2CO2-], exhibit reduced redox activity compared to cobalt mesoporphyrin (Co-MP) and cobalt protoporphyrin (Co-PP), which alleviates the deleterious effects assocd. with administration of Co-P assocd. with oxidative stress, particularly in the context of injection site toxicity. An example compd. of the invention does not trigger generation of reactive oxygen species in SH-SY5Y neuroblastoma cells compared to cobalt protoporphyrin (Co-PP).


IT **435340-45-7P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of cobalt porphyrin complexes as antiobesity agents)

RN 435340-45-7 HCAPLUS

CN Cobalt(1+), [N,N'-bis[(3,4-dimethoxyphenyl)methyl]-7,12-diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanamidato(2-)-.kappa.N21,.kappa.N22,.kappa.N23,.kappa.N24]bis(1H-imidazole-.kappa.N3)-, chloride, (OC-6-13)-(9CI) (CA INDEX NAME)



● Cl<sup>-</sup>

L7 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:15514 HCAPLUS

DOCUMENT NUMBER: 134:204940

TITLE: Efficacies of lipophilic inhibitors of dihydrofolate reductase against parasitic protozoa

AUTHOR(S): Lau, Hollis; Ferlan, Jill T.; Brophy, Victoria Hertle; Rosowsky, Andre; Sibley, Carol Hopkins

CORPORATE SOURCE: Department of Genetics, University of Washington, Seattle, WA, 98195-7360, USA

SOURCE: Antimicrobial Agents and Chemotherapy (2001), 45(1), 187-195

CODEN: AMACCQ; ISSN: 0066-4804

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Competitive inhibitors of dihydrofolate reductase (DHFR) are used in chemotherapy or prophylaxis of many microbial pathogens, including the eukaryotic parasites *Plasmodium falciparum* and *Toxoplasma gondii*. Unfortunately, point mutations in the DHFR gene can confer resistance to inhibitors specific to these pathogens. We have developed a rapid system for testing inhibitors of DHFRs from a variety of parasites. We replaced the DHFR gene from the budding yeast *Saccharomyces cerevisiae* with the DHFR-coding region from humans, *P. falciparum*, *T. gondii*, *Pneumocystis carinii*, and bovine or human-derived *Cryptosporidium parvum*. We studied 84 dicyclic and tricyclic 2,4-diaminopyrimidine derivs. in this heterologous system and identified those most effective against the DHFR enzymes from each of the pathogens. Among these compds., six tetrahydroquinazolines were effective inhibitors of every strain tested, but they also inhibited the human DHFR and were not selective for the parasites. However, two quinazolines and four tetrahydroquinazolines were both potent and selective inhibitors of the *P. falciparum* DHFR. These compds. show promise for development as antimalarial drugs.

IT 328402-39-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(efficacies of lipophilic inhibitors of dihydrofolate reductase against parasitic protozoa)

RN 328402-39-7 HCAPLUS

CN Pentanediamide, 2-[[4-[[[(2,4-diamino-6-pteridiny)methyl]methylamino]benzoyl]amino]-N,N'-bis[(3,4-dimethoxyphenyl)methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

— OMe

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:209882 HCAPLUS

DOCUMENT NUMBER: 132:241970

TITLE: Pharmaceutical compositions containing

INVENTOR(S): N-acylvanillinamide derivatives capable of activating peripheral cannabinoid receptors  
Bisogno, Tiziana; Della Valle, Francesco; De Petrocellis, Luciano; Di Marzo, Vincenzo; Marcolongo, Gabriele; Melck, Dominique

PATENT ASSIGNEE(S): Innovet Italia S.r.l., Italy; Consiglio Nazionale Delle Ricerche

SOURCE: PCT Int. Appl., 68 pp.  
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000016756	A2	20000330	WO 1999-EP6980	19990921
WO 2000016756	A3	20000908		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 1302264	B1	20000905	IT 1998-MI2064	19980924
AU 9960860	A1	20000410	AU 1999-60860	19990921
EP 1115392	A2	20010718	EP 1999-947394	19990921
EP 1115392	B1	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 229330	E	20021215	AT 1999-947394	19990921
PRIORITY APPLN. INFO.:				
			IT 1998-MI2064	A 19980924
			WO 1999-EP6980	W 19990921
OTHER SOURCE(S): MARPAT 132:241970				
AB	Pharmaceutical compns. contg.. N-acylvanillinamide derivs. capable of activating the peripheral receptor CB1 of cannabinoids (Markush structures) are disclosed. N-(4-hydroxy-3-methoxybenzyl)oleylamide (I) was prepd. by the reaction of oleic acid, 4-methylmorpholine, and 4-hydroxy-3-methoxybenzylamine hydrochloride. The specific binding of I to mouse neuroblastoma cells and rat leukemia basophil cell was 1.64 .mu.M and >15 .mu.M, resp. A tablet contained 30, lactose 85, corn starch 75, talc 6, magnesium stearate 2, and CM-cellulose 2 mg.			
IT	<b>261946-50-3P</b> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (pharmaceutical compns. contg. N-acylvanillinamide derivs. capable of activating peripheral cannabinoid receptors)			
RN	261946-50-3 HCAPLUS			
CN	Nonanediamide, N,N'-bis[(4-hydroxy-3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)			



L7 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:847810 HCAPLUS

DOCUMENT NUMBER: 123:329256

TITLE: Synthesis and biological activity of substituted (3,3-dimethyl-1,2,3,4-tetrahydroisoquinolyldiene-1)acet- and malonanilides

AUTHOR(S): Boronenkova, Ye. S.; Syropyatov, B. Ya.; Gorbunov, A. A.; Shklyayev, V. S.; Shklyayev, Yu. V.

CORPORATE SOURCE: Inst. Tekh. Khim., UrO RAN, Perm, Russia

SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1994), (8), 18-21  
CODEN: KHFZAN; ISSN: 0023-1134

PUBLISHER: Meditsina

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB The prepn. and biol. activity of substituted (3,3-dimethyl-1,2,3,4-tetrahydroisoquinolyldiene-1)acetanilides and malonanilides is described and their antiarrhythmic and platelet aggregation inhibiting activity related to the structure. The toxicity of the compds. was also studied.


IT 170658-30-7P


RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. and structure-related biol. activity of substituted isoquinolyldiene acetanilides and malonanilides)

RN 170658-30-7 HCAPLUS

CN Propanediamide, 2-(3,4-dihydro-3,3-dimethyl-1(2H)-isoquinolinylidene)-N,N'-bis[(3,4-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)





L7 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1990:217513 HCAPLUS

DOCUMENT NUMBER: 112:217513

TITLE: New peptide chelating systems. Synthesis of tricatechol peptide based on L-glutamyl-3,4-dimethoxybenzylamine

AUTHOR(S): Pastuszak, J. J.

CORPORATE SOURCE: Dep. Org. Chem., Tech. Univ. Gdansk, Gdansk, PL-80-952, Pol.

SOURCE: Journal fuer Praktische Chemie (Leipzig) (1989), 331(3), 521-4  
CODEN: JPCEAO; ISSN: 0021-8383

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 112:217513

AB Tripeptide amide H-[Glu(NHR)]2-Gly-NHR [R = CH<sub>2</sub>C<sub>6</sub>H<sub>3</sub>(OMe)<sub>2-3,4</sub>], a potential ferric ion ligand, was prepd. by stepwise couplings of phthalyl-.gamma.-glutamylveratrylamine and phthalylglycylveratrylamine.


IT 127106-79-0P 127106-81-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and deblocking of, with hydrazine)

RN 127106-79-0 HCAPLUS

CN Pentanediamide, 2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-N5-[(3,4-dimethoxyphenyl)methyl]-N1-[2-[[[(3,4-dimethoxyphenyl)methyl]amino]-2-oxoethyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 127106-81-4 HCAPLUS

CN Glycinamide, N2-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-5-[[ (3,4-dimethoxyphenyl)methyl]amino]-1,5-dioxopentyl]-N-[(3,4-dimethoxyphenyl)methyl]-L-glutamyl-N-[(3,4-dimethoxyphenyl)methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 127106-82-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT




(Reactant or reagent)  
(prepn. and demethylation of)


RN 127106-82-5 HCAPLUS  
CN Glycinamide, N-[(3,4-dimethoxyphenyl)methyl]-L-glutaminyl-N-[(3,4-dimethoxyphenyl)methyl]-L-glutaminyl-N-[(3,4-dimethoxyphenyl)methyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



IT 127106-80-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and peptide coupling of, with glutamic acid deriv.)  
RN 127106-80-3 HCAPLUS

CN Glycinamide, N-[(3,4-dimethoxyphenyl)methyl]-L-glutaminyl-N-[(3,4-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 127106-83-6P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 127106-83-6 HCAPLUS


CN Glycinamide, N-[(3,4-dihydroxyphenyl)methyl]-L-glutaminyl-N-[(3,4-dihydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



L7 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1986:625922 HCAPLUS  
DOCUMENT NUMBER: 105:225922  
TITLE: The reaction of N-substituted-.alpha.-chloroacetamide  
with potassium tert-butoxide  
AUTHOR(S): Kido, Kazuko; Watanabe, Yasuo  
CORPORATE SOURCE: Daiichi Coll. Pharma Sci., Fukuoka, Japan  
SOURCE: Daiichi Yakka Daigaku Kenkyu Nenpo (1985), 16, 15-20  
CODEN: DYDNM; ISSN: 0286-8016  
DOCUMENT TYPE: Journal  
LANGUAGE: Japanese  
GI



I

AB N-Substituted-.alpha.-chloroacetamides were treated with KOCMe3 in Me3COH at boiling for 8 h to give 1,4-disubstituted-2,5-piperazinediones .alpha.-tert-butoxy-N-substituted acetamides and N, N'-disubstituted diglycolic diamides. Thus, PhCH2NHCOCH2Cl gave 28.9% piperazine I, 29.4% PhCH2NHCOCH2OCMe3, and 6.2% (PhCH2NHCOCH2)2O.

IT 105397-57-7P  
RL: FORM (Formation, nonpreparative); PREP (Preparation)  
(formation of, in reaction of benzylchloroacetamide derivs. with potassium tertiary-butoxide)

RN 105397-57-7 HCAPLUS  
CN Acetamide, 2,2'-oxybis[N-[(3,4-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

